JAX Clinical Knowledgebase - Identify Resistance Variants in Preclinical Drug Testing
One of the major challenges oncologists are often faced with when managing precision cancer treatment is acquired drug resistance.
Learn More
JAX Blog
Learn about new technologies and discoveries focused on precise and personalized treatments for patients.
-
-
Making a Case for Preclinical Data - The JAX Clinical Knowledgebase
The JAX Clinical Knowledgebase (CKB) is a relational database that contains data associated with cancer variants, tumor types, and therapies.
Learn More
-
What are digital badges and why should you consider sharing yours?
As colleges and universities, research institutes and other organizations continue to create more high-quality online courses, these digital badges are becoming a common way for successful...
Learn More
-
Progress with long read sequencing
But wait, didn’t the Human Genome Project accomplish that feat about 20 years ago? The simple answer is no, it did not. The first “complete” human genome sequence was actually complete only in...
Learn More
-
Evidence-based selection of the starting dose in first-in-human clinical trials using humanized mouse models
The dose selection for first-in-human (FIH) clinical trials relies on data obtained by a combination of in vitro and in vivo studies designed to evaluate the efficacy, toxicity, and stability of...
Learn More
-
How To Make Your New NSG Variant in a Fraction of the Time
CRISPR/Cas9 can quickly generate new translational mouse models directly on the genetic background needed for your preclinical research. This saves valuable research time by reducing the need for...
Learn More
-
Achieving Relevant Preclinical Characterization of CAR T Cell Therapies
Introduction Since the first chimeric antigen receptor (CAR) T cell therapy received FDA approval in 2017, this promising immunotherapy modality has only continued to gather momentum. Existing...
Learn More
-
New Fellowship at JAX to Unravel the Complexities Between Aging and Cancer
It’s been long recognized that aging is the single biggest risk factor for cancer and that age impacts treatment response. Research is urgently needed to develop a mechanistic understanding of the...
Learn More
-
A translationally-relevant alternative to non-human primates
Just last week, the Food and Drug Administration (FDA) published recommendations to drug developers and researchers urging them to consider alternatives to non-human primates (NHPs) in general...
Learn More
-
Studying Complex, Systemic Immune Responses in Humanized Mice
Although many mammals have immune systems that share important characteristics with humans, certain immune cell types and phenomena are unique to us. As a result, it has been difficult to design...
Learn More
-
When is pharmacogenomic testing useful in cancer care?
Dr. Kimathi is a medical oncologist in a community setting where she sees patients with a variety of cancer diagnoses. Recently, she had several patients with toxicities to different treatments,...
Learn More
-
Q&A: Studying Cytokine Release Syndrome in a Diverse Population
Our immune system is incredibly complex and powerful—sometimes almost too powerful. Occasionally, it responds to a disease or drug with an inflammatory overreaction known as cytokine release...
Learn More
-
Practicing culturally competent genomic medicine
Cultural competency is defined as the ability to understand, appreciate and interact with people from a culture or belief systems different from one’s own (American Psychological Society 2015)....
Learn More
-
How do I get from here to there? Navigating precision medicine in cancer
This scenario is more complicated than it may seem. With genomic tumor testing, a negative result is not always definitive. In some cases a genomic variant can be present but not detected by the...
Learn More
-
Assessing patient health risks with limited or unknown family history
With November designated as Family Health History month, clinicians are sure to have seen lots of messaging encouraging their patients to discuss family health history around the holiday table....
Learn More
-
Underrepresented, underserved and understudied
Frustrated about lack of actionable results in genetic testing Donna is a 60-year-old Black woman with a personal history of breast cancer, diagnosed at age 49. Her oncologist recommended she...
Learn More
-
Diversity Mice User Guide
This user guide is designed to introduce you to the core concepts of genetic diversity, present diversity models, and their key features.
Learn More
-
Important Considerations for Generating Genetic Humanized Mouse Models
The term humanization is used, to much confusion, to mean several different things in mouse research. While broad in scope and technique, all humanized mouse models share a common goal – to better lev
Learn More
-
Kids at risk? When parents should consider hereditary cancer testing for their children.
If you’ve been following our blog or participating in our courses, you’ll know that there are many hereditary cancer syndromes that increase adults’ lifetime cancer risks. Often, adults undergoing...
Learn More
-
Wearables, clinical data and COVID-19
Like one in five Americans, I wear a watch that also tracks several health-related statistics through the day. It tells me how well I slept, how many steps I took, how high my heart rate got...
Learn More
-
Loading More...
